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The clinical use of Sodium nitroprusside (SNP) may be associated with an alteration of platelet function. The main
focus of this study was the effect of SNP on platelet aggregation in the absence or presence of endothelial cells.
Methods: Platelets were incubated with different concentrations of SNP with and without endothelial cells. Platelet
aggregation was induced by ADP.
Results: Platelet aggregation was significantly inhibited by all concentrations of SNP. Endothelial cells significantly
increased this inhibitory effect of SNP. Time course studies showed an inverse correlation of incubation time to
platelet aggregation inhibition in the absence of endothelial cells, and a direct correlation in the presence of
endothelial cells. Blocking platelet and endothelial cell guanylate cyclase with 1 H-(1,2,4)-oxadiazolo(4,3-a)
quinoxalin-1-one (ODQ), or pretreatment of the endothelial cells with cyclooxygenase – inhibitors, had no influence
on the increased inhibitory effect of the endothelial cells. Cyanide reversed the inhibitory effect of SNP completely.
Conclusion: Endothelial cells play an important role in the SNP mediated inhibition of platelet aggregation. The
effect is reversible only by cyanide, not by blocking classical NO signal transduction.
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The administration of Sodium nitroprusside (SNP) is a
highly effective strategy in pulmonary and systemic
hypertension crisis, both in adults and in neonates [1,2].
The most common SNP application is intravenous, but
inhalation and endotracheal application is used as well
[3,4]. The main mechanism of action may be explained
by the release of NO which results in a dilation of small
vessels both in the systemic and the pulmonary circula-
tion. A well known side effect of NO is the inhibition of
platelet function [5,6]. This interference of platelet acti-
vation is due to the stimulation of the soluble guanylate
cyclase which increases the concentration of cGMP and
inhibits the calcium-dependant platelet activation [7].
Just recently Jensen et al. published a study on the po-
tential synergistic effect of Dipyridamole and NO
donors, such as sodiumnitroprusside, to prolong the in-
hibition of thrombin-induced platelet shape change. [8]* Correspondence: hans-georg.topf@uk-erlangen.de
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reproduction in any medium, provided the orSimilar results confirming the synergistic effect of NO
donors and other antiplatelet drugs, could be demon-
strated by Negrescu et al. [9]. In addition, Suzuki and
coworkers suggest a synergistic effect of SNP and fi-
brinolytic agents [10]. In vitro studies have shown that
NO inhibits platelet adhesion to endothelial cells [11] as
well as platelet aggregation [12,13], platelet activation
[5-7,14,15] and clot formation [16,17] and thrombus
growth under shear stress [18]. However, these results
could not always be confirmed by in vivo studies. Several
studies have been performed investigating the mechan-
ism of SNP action on platelet aggregation, but the exact
means of interaction still is not understood [19,20]. Most
authors confirm the NO dependent inhibition of platelet
activation by SNP. Woods and coworkers clearly demon-
strated that the platelet response to SNP in hyperten-
sives is lower due to reduced sensitivity of the platelets
to NO [21]. Sogo and coworkers showed that in the ab-
sence of endothelial cells the effect of SNP is exclusively
cGMP dependent, which is in accordance with our
results [22]. In addition this direct interference withd .This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity in endothelial cells, resulting in increased concentra-
tions of prostacyclins and the subsequent inhibition of
platelet activation [23-25].
As well as this NO dependent effect other mechanisms
seem to have an important impact on the inhibitory ac-
tion of SNP in the presence of endothelial cells. Levin
et al. already mentioned that the supernatant taken from
SNP-incubated endothelial cells, had a surprising inhibi-
tory effect on platelet aggregation not due to NO alone
[26].
In the present study we wanted to evaluate the role of
endothelial cells on the antiaggregatory effect of SNP.
An additional aim was to investigate wether the time
span between the incubation of platelets with SNP and
measurement of the antiaggregatory effect provides an
explanation for the sometimes contradictory results of
in vitro and in vivo studies. The third goal was to test
the reversibility of the antiaggregatory effects of SNP by
cyanide and classical NO pathway inhibition.
Material and methods
Reagents
Sodium nitroprusside (SNP), Cyanide and ADP were pur-
chased from Sigma laboratories and 1 H-(1,2,4)oxadia-
zolo(4,3-a)quinoxalin-1-one (ODQ) was purchased from
Alexis Biochemicals. PBS was obtained from Boehringer,
Germany and Protaminhydrochloride (Protamin ICN
1000) was from ICN, Frankfurt, Germany. Acetyl sali-
cylic acid (ASS) was obtained from Bayer, Leverkusen,
Germany and indomethacin (Liomethacin) was purchased
from Chiesi Pharmaceutica, Parma, Italy.
Endothelial cell culture
For the endothelial cell experiments we used a well
established configuration using human umbilical endo-
thelial cells (HUVEC). HUVEC were isolated from fresh
human umbilical cord vein by enzymatic disaggregation
with collagenase, and were used between passages 2
and 5. HUVEC were cultured as previously described
[27], the plates were washed with PBS before the blood
sample was added and Heparin was neutralized with 75
I.U. of Protamin. Blood samples Venous blood was
drawn from 4 healthy volunteers and coagulation was
prevented immediately using 3.8% sodium citrate 1:10.
The volunteers took no medication two weeks prior to
blood sampling.
Incubation with SNP
The effect of different concentrations of SNP and differ-
ent incubation times was tested. After adding SNP to
5 mL of whole blood, samples were placed on culture
plates. A new plate was used for each concentration and
incubation time. Samples without SNP were used ascontrols. To study the effect of endothelial cells on ag-
gregation, the incubation was performed on culture
plates with, and without endothelial cells.
SNP concentrations were 100 μM, 500 μM and
1000 μM. Time course studies were performed with
100 μM SNP, and incubation times of the whole blood
samples were 0, 1, 2 and 4 hours.
As total centrifugation time was 20 minutes (s. below)
and SNP was added to the whole blood sample before
centrifugation contact time between SNP and platelets
was at least 20 minutes. Samples were kept at 37°C dur-
ing the whole experiment.
Mechanism of SNP – mediated inhibition of platelet
function
We wished to study the mechanism by which SNP
inhibits platelet aggregation. NO signal transduction
by cGMP was inhibited using the guanylate cyclase
inhibitor 1 H-(1,2,4) oxadiazolo(4,3-a)quinoxalin-1-one
(ODQ). ODQ (100 μM) was added to the sample 2 min-
utes before adding 100 μM SNP to allow the reaction of
ODQ with the guanylate cylcase. Platelet rich plasma
was then obtained from the blood sample. The platelet
function was tested using the Born method. Aggregation
was induced with ADP (20 μM) after the platelet count
had been adjusted to 250,000/μL.
To study whether SNP has an effect on the endothelial
production of prostaglandins by activating cyclooxy-
genases (COX I and II), two cyclooxygenase inhibitors,
acetylsalicylic acid and indomethacin were used. Endo-
thelial cells were incubated for 5 min with 3 ml of either
1 mM acetylsalicylic acid or 10 μM indomethacin. Suffi-
cient suppression of the cyclooxygenases in HUVEC by
ASA or indomethacin has been previously described
[28]. After thorough washing with PBS the experiments
were repeated as described above.
To study the effect of cyanide on the effect of SNP, we
added cyanide to whole blood in one set-up. In another
experiment we added cyanide to platelet rich plasma
(PRP) after the addition of ADP. A control group proved
that cyanide itself has no effect on platelet aggregation.
Platelet aggregation
For preparation of platelet-rich plasma the whole blood
samples were centrifuged for 10 minutes at 800 r.p.m.
Platelet-poor plasma was obtained by further centrifuga-
tion of PRP at 3800 r.p.m for 10 minutes. Platelet count
was then adjusted with PPP to 250,000/μL. Platelet re-
sponse to ADP (20 μM) was recorded with a Lumiag-
gregometer (Aggregometer 840, Elvi).
Data analysis
Data represent the mean +/− SD of at least 4 experiments.
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detected every 20 seconds for 6 minutes. The following
parameters were used for statistical analysis: For each
experiment, all values of the aggregation curves were
compared. Data were analyzed with Prism 3.0 using the
Kruskal-Wallis-test and p ≤ 0.05 was accepted as being
significant. In case of multiple comparisons p – values
were corrected according to Dunn. Results were grouped
according to incubation time: Group 1 = no incubation
time, group 2 = incubation time of 1 hour, group 3 = in-
cubation time of 2 hours, group 4 = incubation time of
4 hours.Results
The difference in platelet aggregation of controls with,
and without, endothelial cells was not significant differ-
ent. (Additional file 1 1st and 3rd column). We could
show that ADP induced thrombocyte aggregation was
intact even 4 h after blood sampling, with and without
endothelial cells.
Effect of SNP on platelet aggregation, effect of
endothelial cells
After 1 hour of incubation SNP inhibited platelet aggre-
gation in a dose-dependent manner. 100 μM, 500 μM
and 1000 μM of SNP were tested (data not shown). This
was statistically significant for all concentrations of SNP.
These experiments were not repeated with endothelial
cells. Time course studies were performed with 100 μM
of SNP, as the 100 μmol curve at one hour was at the
middle of normal aggregation and total inhibition, so
changes in both directions would be detectable. A time
dependent reduction of platelet aggregation could be
detected with an inverse correlation to incubation time.
Endothelial cells significantly increased the SNP –
mediated inhibition of platelet function after 2 and
4 hours of incubation (Additional file 1 2nd and 4th
column).
Effect of ODQ on SNP mediated inhibition of platelet
aggregation
Incubation with ODQ decreased the effect on platelet ag-
gregation at 0 h of incubation time. ODQ did not inhibit
the SNP mediated-effect on platelet aggregation later in
the presence of endothelial cells. (Additional file 1 6th
column)
Effect of COX-inhibition on SNP mediated reduction of
platelet aggregation
Since endothelial cells play an important role in the
SNP-induced inhibition of platelet aggregation, the effect
of COX inhibitors and of ODQ was tested only after in-
cubation with endothelial cells. The cox inhibitors acetylsalicylic acid and indomethacin (in the graph called
COX I) did not influence the effect of SNP on platelet
aggregation. The results were therefore combined. The
pretreatment of endothelial cells with COX inhibitors
did not interfere with the effect of SNP incubation
(Additional file 1 7th column).
Effect of cyanide on SNP mediated inhibition of platelet
aggregation
Cyanide (2000 μM) alone did not influence platelet
aggregation. Cyanide added to whole blood prior to
addition of SNP repressed the effect of SNP in all cases.
The addition of cyanide after the preparation of platelet-
rich plasma, prior to the addition of ADP only inhibited
the SNP effect of the endothelial cell experiments
(Additional file 1 5th column).
Discussion
In our study we could clearly demonstrate that endothe-
lial cells play an important role in the antiaggregatory ef-
fect of SNP. Incubation with endothelial cells increased
both the inhibitory effect on platelet aggregation and the
duration of this effect. Levin et al. already mentioned
that the supernates taken from SNP-incubated endothe-
lial cells had an inhibiting effect on platelet aggregation
[26]. They speculated that their data could be explained
by the synergy of NO and PGI2 [26]. The Levin study
used supernatants of SNP-incubated endothelial cells
and did not preincubate the endothelial cells with
cyclooxygenase inhibitors, which may have led to differ-
ent results. In contrast to their experimental setting, the
platelets in our study were in direct contact with the
endothelial cells during SNP incubation, which suggests
possible additional interactions between platelets and
endothelial cells. It has been well established that PGs of
the E series and PGI2 inhibit platelet aggregation by
counteracting the proaggregatory effect of thromboxane
A2 [29]. This could explain the additional inhibitory
affect of the endothelial cells in the presence of NO.
However, this explanation seems insufficient, as the pre-
incubation of endothelial cells with cyclooxygenase inhi-
bitors, suppressing the PGI2 production, did not change
the SNP effect as expected. In an earlier study we could
show that the effect of other NO-donors, such as SNAP,
is increased by the PG pathway. Induction of PGI2 via
NO, following reduced platelet aggregation, could be
blocked by preincubation of the endothelial cells with
cyclooxygenases [28]. The effect of SNP was not attenu-
ated by the preincubation of the endothelial cells with a
cyclooxygenase inhibitor. This is in contrast to the con-
clusions of Levin and coworkers [26]. Sogo et al. could
clearly demonstrate that, in the absence of endothelial
cells, the effect of SNP is exclusively cGMP-dependent
[22], which should be the case if the effect is due to NO
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by the guanylate cyclase inhibitor ODQ, which is sup-
posed to block the cGMP-dependent NO effect. This
opposes the hypothesis that the effect of SNP is exclu-
sively cGMP dependent in the presence of endothelial
cells. These results highlight the importance of the
endothelial cell in SNP metabolism and platelet inter-
action. Our data do not allow us to decide which path-
way is responsible for the results measured. Because the
effect of endothelial cells on platelet aggregation could
not be reversed by incubation with a COX-inhibitor, we
speculate that activation of endothelial cyclooxygenases by
SNP may not be too important for the antiaggregatory ef-
fect of SNP.
Our results without endothelial cells show an effect of
SNP on platelets which is in accordance with other
in vitro studies [7,26,30].
Another interesting fact is that the addition of cyanide
is able to reverse the effect, not only after immediate ad-
ministration, as shown by Brune et al. [5], but even after
4 h of incubation with SNP. This effect has not been
described before in the literature. Although we do not
have an explanation for this observation, we speculate
that a cGMP independent pathway may be responsible
for this effect.
In summary, our results show that endothelial cells
play an important role in the SNP- mediated inhibition
of platelet activation, which can be reversed only by
cyanide. We could demonstrate that this effect is not
mediated by activation of endothelial cyclooxygenases,
as the inhibition of cyclooxygenases had no influence on
the results. It is not dependent on cGMP, as it is not
influenced by the guanylate cyclase inhibitor ODQ. Thus
we suggest a cGMP independent, possibly not yet known
pathway for platelet inhibition by SNP/endothelial cells.
The identification of this unknown antiaggregatory
metabolite could be of great interest, since its effect on
ADP-dependent platelet aggregation is long-lasting, but
reversible by cyanide. We speculate that other less toxic
ion metabolites could also reverse this effect, thus offer-
ing the opportunity for antidot treatment.
Additional file
Additional file 1: Comparison of aggregation at timepoints 0, 1, 2
and 4 hours.
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